ArticleAnnals of hematology2026
Donor-source-specific competing risks of relapse and non-relapse mortality in adult B-ALL allogeneic hematopoietic stem cell transplantation on a rabbit antithymocyte globulin-based platform.
Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a cornerstone of therapy for adult B-cell acute lymphoblastic leukemia (B-ALL), yet simultaneous comparison of all four major donor categories within a single transplant platform is scarce. We retrospectively analyzed 190 consecutive adults with B-ALL undergoing first allo-HSCT (2008-2025) at a single center on a predominantly rabbit antithymocyte globulin (rATG)-based myeloablative platform: matched sibling (MSD, n = 72), matched unrelated (MUD, n = 46), mismatched unrelated (MMUD, n = 40), and haploidentical (Haplo, n = 32) donors. Cumulative incidence of relapse (CIR) and non-relapse mortality (NRM) were compared in a competing-risk framework (Fine-Gray regression). Five-year overall survival did not differ significantly across donor groups (range 31.6-59.2%; P = 0.14). Competing-risk analysis revealed opposing gradients: five-year CIR decreased from MSD (38.5%) to Haplo (23.8%; P = 0.40), whereas NRM increased from MSD (13.3%) to Haplo (43.5%; P = 0.01). Relapse-free survival did not differ (P = 0.43). Haploidentical transplantation was independently associated with higher NRM (subdistribution hazard ratio [sHR] 4.44; P < 0.001) but not relapse, compared with MSD. NRM was infection-related in 29/39 patients (74%; 83% in Haplo), whereas graft-versus-host disease (GVHD)-related deaths were rare. After inverse-probability-of-treatment weighting, NRM remained higher in haploidentical recipients (31.9% vs. 17.7%), while the apparent CIR advantage attenuated (38.2% vs. 34.8%). Within a predominantly rATG-based platform, donor source produced opposing gradients of relapse and NRM, with the apparent haploidentical relapse advantage largely explained by age and era confounding. The persistent NRM excess in haploidentical recipients was driven predominantly by infection rather than GVHD. These platform-specific findings support transitioning to post-transplant cyclophosphamide (PTCy)-based approaches.
Indexed as
Identifiers
42881285What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.